SUVEN2024-04-012024-06-30 SUVEN2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member SUVEN2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member SUVEN2024-06-30 SUVEN2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 530239 SUVEN NOTLISTED Suven Life Sciences Limited Equity 2024-04-01 2025-03-31 2024-08-05 2024-07-29 INR Lakhs First quarter 12:00:00 12:55:00 2024-08-05 2024-08-05 Not applicable Single segment The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented 2024-04-01 2024-06-30 Unaudited Standalone 10060000.00 39310000.00 49370000.00 0.00 0.00 0.00 46896000.00 231000.00 14864000.00 64038000.00 126029000.00 -76659000.00 0.00 -76659000.00 0.00 0.00 0.00 0.00 -76659000.00 0.00 0.00 0.00 0.00 -76659000.00 -45000.00 -76704000.00 0.00 0.00 218074000.00 1 -0.35 -0.35 0.00 0.00 -0.35 -0.35 Notes: 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 05, 2024.The results for the quarter ended June 30, 2024 has been reviewed by our statutory auditors. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The Company has alloted 72691239 equity shares amounting to Rs.39980.18 lakhs through rights issue on November 16,2022. Summary of Utilisation of Proceeds of Rights issue Particulars Amount Rs.In lakhs Amout Raised through Rights Issue of Shares 39980.18 Less: Rights Issue Expenses -280.00 Less: Amount Utilised -28685.17 Balance Amount 11015.01 6) The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year. Other Expenses 18140000.00 R & D Expenses 45898000.00 Items that will not be reclassified to profit & loss -45000.00 -45000.00 0.00 0.00